PF-04457845

Ligand id: 6694

Name: PF-04457845

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 80.24
Molecular weight 455.16
XLogP 5.66
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
PF-04457845 has not progressed beyond Phase II clinical investigation for pain (associated with osteoarthritis of the knee) and post-traumatic stress disorder (PTSD). Additional Phase II trials are evaluating PF-04457845 in patients with Tourette syndrome, in fear conditioning and patients with cannabis dependence. Click here to link to ClinicalTrials.gov's Phase II PF-04457845 records.
Mechanism Of Action and Pharmacodynamic Effects
FAAH is a serine hydrolase enzyme of the endocannabinoid system which is responsible for the catabolic inactivation of the neuromodulator anandamide. FAAH inhibitors cause a build up of anandamide, which acts through activation of cannabinoid receptors to promote analgesia, and may have anti-inflammatory action [4] and prove beneficial in managing psychiatric disorders [1,3].